Company research
Ceribell, Inc.
CIK 1861107Updated Sep 27, 2026
SecurityCBLL · NASDAQ · equity
CBLL price & chart
Loading TradingView…
NASDAQ:CBLL on TradingView ↗About the company
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
In the news
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 195,803,000Source | 225,412,000Source | 58,922,000Source |
| Property, Plant and Equipment, NetUSD | 2,030,000Source | 2,313,000Source | 1,577,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 40,476,000Source | 194,370,000Source | 34,495,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 15,053,000Source | 10,878,000Source | 7,955,000Source |
| Inventory, NetUSD | 7,288,000Source | 6,937,000Source | 5,868,000Source |
| Assets, CurrentUSD | 186,718,000Source | 217,272,000Source | 51,963,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,906,000Source | 3,250,000Source | 2,130,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,296,000Source | 2,132,000Source | 2,160,000Source |
| Other Assets, NoncurrentUSD | 2,912,000Source | 2,188,000Source | 1,984,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 40,467,000Source | 34,247,000Source | 23,762,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 38,000Source | 36,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -220,356,000Source | -166,944,000Source | -126,489,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 159,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 155,336,000Source | 191,165,000Source | -112,252,000Source |
| Additional Paid in Capital, Common StockUSD | 375,495,000Source | 358,073,000Source | 14,232,000Source |
| Liabilities and EquityUSD | 195,803,000Source | 225,412,000Source | 58,922,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 19,190,000Source | 12,989,000Source | 21,600,000Source |
| Operating Lease, Liability, CurrentUSD | 1,105,000Source | 1,088,000Source | 694,000Source |
| Accounts Payable, CurrentUSD | 2,838,000Source | 1,143,000Source | 732,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,360,000Source | 1,314,000Source | 1,677,000Source |
| Other Liabilities, NoncurrentUSD | 106,000Source | 356,000Source | 441,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 14,328,000Source | 10,052,000Source | 7,540,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 159,300,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -53,412,000Source | -40,455,000Source | -29,464,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 1,341,000Source | 1,141,000Source | 847,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,223,000Source | 5,411,000Source | 2,678,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 4,175,000Source | 2,923,000Source | 2,660,000Source |
| Increase (Decrease) in InventoriesUSD | 351,000Source | 1,068,000Source | 1,794,000Source |
| Increase (Decrease) in Accounts PayableUSD | 1,745,000Source | 250,000Source | 309,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -40,808,000Source | -35,043,000Source | -29,159,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -118,137,000Source | -1,598,000Source | -1,763,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 767,000Source | 1,340,000Source | 983,000Source |
| Cash flows from financing activities: | |||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 236,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,051,000Source | 196,516,000Source | -2,818,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -153,894,000Source | 159,875,000Source | -33,740,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 40,476,000Source | 194,370,000Source | 34,495,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,894,000Source | 1,952,000Source | 1,734,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 12,223,000Source | 5,411,000Source | 2,678,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 159,300,000Source | — | — |
| DepreciationUSD | 300,000Source | 400,000Source | 300,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -104,000Source | -95,000Source | -181,000Source |
| General and Administrative ExpenseUSD | 44,451,000Source | 33,842,000Source | 20,287,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | 11,000Source |
| InterestExpenseNonoperatingUSD | 1,890,000Source | 1,992,000Source | 2,098,000Source |
| Net Income (Loss) Attributable to ParentUSD | -53,412,000Source | -40,455,000Source | -29,464,000Source |
| Operating ExpensesUSD | 136,676,000Source | 96,459,000Source | 68,204,000Source |
| Other Nonoperating Income (Expense)USD | 6,880,000Source | 2,742,000Source | 2,638,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 89,063,000Source | 65,444,000Source | 45,225,000Source |
| Cost of Goods and Services Sold | — | — | — |
| Operating Income (Loss)USD | -58,402,000Source | -39,709,000Source | -30,041,000Source |
| Other Nonoperating Income (Expense)USD | 6,880,000Source | 2,742,000Source | 2,638,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -53,412,000Source | -40,455,000Source | -29,453,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | 11,000Source |
| Net Income (Loss) Attributable to ParentUSD | -53,412,000Source | -40,455,000Source | -29,464,000Source |
| Earnings Per Share, BasicUSD per share | -1.46Source | -3.39Source | -5.56Source |
| Earnings Per Share, DilutedUSD per share | -1.46Source | -3.39Source | -5.56Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 36,542,048Source | 11,949,973Source | 5,303,715Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 36,542,048Source | 11,949,973Source | 5,303,715Source |
| Interest Expense (non-operating)USD | 1,890,000Source | 1,992,000Source | 2,098,000Source |
| Additional Financial Items | |||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,000,000Source | 700,000Source | 500,000Source |
| General and Administrative ExpenseUSD | 44,451,000Source | 33,842,000Source | 20,287,000Source |
| Gross ProfitUSD | 78,274,000Source | 56,750,000Source | 38,163,000Source |
| Operating ExpensesUSD | 136,676,000Source | 96,459,000Source | 68,204,000Source |
| Research and Development ExpenseUSD | 19,143,000Source | 13,562,000Source | 8,995,000Source |
| Selling and Marketing ExpenseUSD | 73,082,000Source | 49,055,000Source | 38,922,000Source |
Filing attachments
cbll-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 cbll-ex99_1.htm EX-99.1 EX-99.1 Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. - August 10, 2026 - CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 & Recent Highlights • Reported total revenue of $28.1 million in the second quarter …
Read attachment ↗cbll-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 cbll-ex99_1.htm EX-99.1 EX-99.1 Ceribell Reports First Quarter 2026 Financial Results Sunnyvale, Calif. - May 11, 2026 - CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights • Reported total revenue of $26.5 million in the first quarter of 202…
Read attachment ↗cbll-ex99_1.htm · 8-K · 2026-02-24
EX-99.1 2 cbll-ex99_1.htm EX-99.1 EX-99.1 Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results Sunnyvale, Calif. - February 24, 2026 - CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights • Reported total revenue of $2…
Read attachment ↗cbll-ex99_1.htm · 8-K · 2026-01-05
EX-99.1 2 cbll-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting SUNNYVALE, Calif., January 5, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical techno…
Read attachment ↗cbll-ex99_1.htm · 8-K · 2026-01-02
EX-99.1 2 cbll-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 12/30/2025 Rebecca Robertson Board Chair Ceribell 360 N Pastoria Avenue Sunnyvale, CA 94085, USA Subject: Resignation from the Board of Directors Dear Rebecca Robertson and Members of the Board, Please accept this letter as formal notification of my decision to resign as a member of the Board of Directors of Ceribell, effective December 31, 2025. My decision is based purely on a desire to focus on other professional ventures, and …
Read attachment ↗cbll-ex99_1.htm · 8-K · 2025-12-09
EX-99.1 2 cbll-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., December 9, 2025 -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patien…
Read attachment ↗